Boston, MA According to CBRE/New England, Acetylon Pharmaceuticals, a leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, renewed its 13,600 s/f lease at 451 D St. in the city’s Seaport District. Acetylon occupies both laboratory and office space in the building.
McPherson Corp.’s Keith Coulter represented Acetylon in the transaction. CBRE/NE’s Bill Crean and Jonathan Freni represented owner, Meritage Properties. The building is owned in a joint venture between Meritage Properties, State Street Global Advisors and Commonwealth Ventures.
“We are thrilled that Acetylon Pharmaceuticals, another high-quality and innovative company, will continue to call 451 D home,” said Erin Shaw, managing director at Meritage Properties. “451 D has a unique ability to accommodate the needs of both large and small tenants in a highly amenitized industrial chic environment, just steps from The Lawn on D.”
“451 D St. has the vibrant location, terrific on-site amenities and community of like-minded tenants that make it appealing to practically every organization seeking a Boston presence,” said Crean, senior vice president/partner at CBRE/NE. “We are glad that Acetylon continues to see the value that 451 D St. offers for its employees and business.”
451 D St. offers amenities including on-site parking, a fitness center and shuttle service to North and South Stations. The property is currently undergoing a lobby renovation and the addition of a 3,000 s/f tenant amenity center featuring a lounge area, kitchen, games and conference center.
